Evidence map›Paper›PMID 9049884›Full record

ArticleJournal of neuro-oncology1997

p53 protein in pediatric malignant astrocytomas: a study of 21 patients.

M B Bhattacharjee, J M Bruner

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. H3K27M, IDH1, and ATRX expression in pediatric GBM and their clinical and prognostic significance.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2019
    Article
  3. A study of histopathological spectrum and expression of Ki-67, TP53 in primary brain tumors of pediatric age group.Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology · 2012
    Article
  4. MGMT gene promoter methylation in pediatric glioblastomas.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2010
    Article
  5. Characterization of glioblastomas in young adults.Brain pathology (Zurich, Switzerland) · 2006
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

M B BhattacharjeeDepartment of Pathology (Neuropathology), Baylor College of Medicine, Houston, USA.
J M Bruner
Baylor College of Medicine · USThe University of Texas MD Anderson Cancer Center · US

Funding

PROTEASES IN BRIAN TUMORS PROGNOSTIC SIGNIFICANCEP01CA055261 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI LEVIN, VICTOR A · 1992 to 2000
$1.0M
NCI NIH HHS P01 CA55261-04
6 · The paper itself

Abstract

Malignant astrocytomas are uncommon brain tumors in children and it is known that astrocytic tumors with similar degrees of histologic anaplasia often show different biologic behaviour. Their uncommon occurrence has resulted in relatively few studies of the molecular biology and genetics of pediatric malignant astrocytomas with somewhat conflicting results, in contrast with the many studies addressing astrocytomas in adults. p53 immunoreactivity has been used to screen tissues for the abnormal presence of the p53 protein and abnormal immunoreactivity has been demonstrated in one-half to two-thirds of adult astrocytomas. We studied the frequency of p53 immunoreactivity and gene alteration in 21 children with malignant astrocytomas (anaplastic astrocytoma and glioblastoma multiforme) and analysed the survival of patients with p53 immunoreactive versus non-reactive tumors. Of the cases examined, 8 were anaplastic astrocytoma (AA) and 13 were glioblastoma multiforme (GM). We found that the overall frequency of p53 immunoreactivity of 47% in this group of pediatric malignant astrocytomas is similar to that reported for adult astrocytomas. The median survival in both p53-positive and p53-negative groups of pediatric malignant astrocytomas was similar: however, the number of deaths in each group and the distribution of p53 scores is not statistically significant. Further studies to precisely identify p53 and other genetic mutations in pediatric gliomas are needed to understand their biology and the rationale for therapeutic options.

Indexed as

MutationAdolescentBrain NeoplasmsChildChild, PreschoolFemaleGenes, p53GlioblastomaHumansImmunohistochemistryInfantInfant, NewbornMaleSequence Analysis, DNATumor Suppressor Protein p53Tumor Suppressor Protein p53

Identifiers

PMID9049884
OpenAlexW113753897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.